Open Hours: Mon- Sat 10:00 am - 06:30pm
Women’s healthcare in India has moved from a quiet, overlooked corner of the pharma industry to one of its steadiest-growing segments. More gynecologists are opening practice, fertility treatment awareness has grown considerably, and hormone therapy and prenatal care have become far less taboo topics than they were even a decade ago. That growth is exactly what’s fueling demand for a gynae PCD franchise — a business model letting entrepreneurs build a focused, recurring-revenue pharma business without manufacturing a single tablet themselves.
This guide covers what a gynae PCD franchise actually involves, how to start one, what it costs, and why Novalab Gynae Care — an ISO-certified, WHO-GMP gynecology and infertility specialist based in Panchkula — has become a serious option for partners who want a company genuinely built around one therapeutic focus instead of a scattered general catalogue.
Table of Contents
TogglePCD stands for Propaganda Cum Distribution. A pharma company grants you rights to market and sell its products within a defined territory, using its brand name and packaging. Add “gynae” to that, and you’re working specifically within women’s health — hormone therapy, birth control, fertility support, prenatal and postnatal care, and related gynecological formulations.
What makes this category distinct is the prescriber base. Instead of chasing every general physician in a district, a gynae PCD partner builds focused relationships with a smaller, more specialized group — gynecologists, obstetricians, and fertility specialists. Fewer relationships to manage, but each one carries more weight, since gynecologists tend to prescribe consistently once they trust a brand’s quality and reliability.
Novalab Gynae Care’s own range reflects this focus well. Beyond standard tablets, the portfolio spans syrups, injectables, and mix products — covering hormone therapy, birth control, multivitamins, and gastro medicines built specifically around female healthcare needs, giving a partner enough range to serve a gynecologist’s full prescribing pattern under one brand.
Here’s the actual sequence, without the padding most guides give you.
Step 1: Sort your license paperwork first. A Drug License (retail and/or wholesale) from your state’s Drug Control Department is required, along with GST registration and a TIN number. Get these in place before approaching any franchise company — it noticeably speeds up onboarding.
Step 2: Map the gynecologists and fertility clinics in your territory. This category lives or dies on relationship density. A district with three active gynecologists and two fertility clinics needs a very different approach than one with fifteen. Know your prescriber landscape before committing capital to stock.
Step 3: Vet the company’s certifications and specialization depth. ISO certification, WHO-GMP manufacturing, and DCGI-approved formulations matter everywhere in pharma, but they matter even more in gynae, where product trust directly affects sensitive treatment decisions like hormone therapy and fertility support.
Step 4: Lock in monopoly and territory terms in writing. Verbal assurances about exclusive rights don’t hold up in a dispute. Make sure your agreement names the exact territory and what happens if the company later wants to adjust it.
Step 5: Order your starter range and start visiting gynecologists directly. Use the promotional material provided — MR bags, diaries, product literature — but treat in-person visits as the real driver. Gynecologists, more than most specialists, prescribe based on trust built through consistent, informed conversations, not just brochures left at reception.
Step 6: Track prescription patterns and expand thoughtfully. Once your hormone therapy or fertility range starts moving consistently, talk to your franchisor about adding adjacent categories — prenatal supplements, gastro support for pregnancy-related issues — that fit naturally into a gynecologist’s existing prescribing habits.
Not every gynae PCD franchise company deserves your capital, even when the certifications look similar on the surface. Here’s what actually separates the reliable ones.
Certification depth matters more here than in general pharma categories. ISO certification and WHO-GMP manufacturing confirm quality standards, but for gynae specifically, look for a company that explicitly states DCGI approval across its hormone and fertility formulations — this is exactly the kind of documentation a cautious gynecologist will ask for before prescribing a new brand to patients undergoing fertility treatment.
Range depth within the specialty matters too. A company offering only birth control tablets limits your growth ceiling fast. Novalab Gynae Care’s range covers hormone therapy, birth control, multivitamins, and gastro medicines together, which means a partner can serve a gynecologist’s broader prescribing needs — not just one narrow slice of it — under a single franchise relationship.
Then there’s specialization itself as a trust signal. A company that focuses entirely on women’s health, rather than treating gynae as one division among a dozen unrelated categories, tends to build deeper product expertise and better-informed promotional material. That specialization is often what convinces a skeptical gynecologist to give a new brand a genuine trial in the first place.
Monopoly works the same way here as across pharma broadly, but it carries extra weight in gynae because the prescriber base is smaller and more concentrated. A monopoly PCD pharma franchise gives you exclusive rights to sell within a defined territory — no competing partner from the same company chasing the same handful of gynecologists in your district.
Novalab Gynae Care structures its franchise offering around monopoly-based distribution rights specifically to avoid internal competition among its own partners. Before signing, confirm your exact territory boundary and duration in writing, and clarify what happens if the company wants to modify or split that territory as it expands into new regions.
Because the gynae prescriber base is naturally smaller than general medicine, monopoly protection matters proportionally more here. Losing exclusivity in a district with only a handful of active gynecologists can hurt a lot more than losing it in a general medicine territory with dozens of prescribers to work with instead.
A gynecology PCD franchise typically spans several distinct product families, and understanding them helps a new partner plan their approach.
Hormone therapy medicines address conditions ranging from menstrual irregularities to menopause management — a category requiring particular trust, since patients are often on these medications for extended periods. Birth control formulations, similarly, need consistent reliability since patients depend on them for predictable, ongoing use. Multivitamins and prenatal supplements support pregnancy and general reproductive health, often prescribed alongside other treatments rather than as standalone purchases. And infertility-focused medicines — supporting conception and early pregnancy — sit at the more specialized, higher-trust end of the category, usually prescribed by fertility specialists working closely with patients over months of treatment.
Novalab Gynae Care’s portfolio, including products like FOLITOSS XT and DIENOCRED, spans several of these families, giving partners the flexibility to build relationships across a gynecologist’s full range of prescribing needs instead of pitching just one narrow product line.
Infertility treatment has grown into a significant segment of Indian healthcare, driven by rising awareness, delayed family planning trends in urban areas, and growing acceptance of fertility treatment as a normal medical path rather than something to hide.
An infertility medicine franchise sits at a more specialized end of the gynae category. Fertility specialists tend to work closely with a smaller set of trusted brands over the course of a patient’s treatment journey, which means the relationship-building bar is higher, but the resulting loyalty tends to run deeper and last longer once established. A partner focusing here needs patience in the early months — building trust with fertility specialists takes longer than general prescribing relationships — but the reorder consistency once that trust is built tends to be strong, since treatment protocols often span multiple months per patient.
Real numbers, not vague brochure ranges.
Most partners start a low investment PCD pharma franchise in the gynae category with somewhere between ₹40,000 and ₹1 lakh, covering the initial stock order across tablets, syrups, and select injectable products. This tends to land in a similar range to other specialty pharma categories, since gynae products don’t typically carry the storage complexity that categories like injectable critical care sometimes do.
Add your drug license fee (₹3,000-₹10,000 depending on the state), promotional material — often subsidized by the franchisor — and two to three months of working capital before repeat prescriptions start generating consistent cash flow. All-in, a realistic starting budget sits between ₹50,000 and ₹1.2 lakh for most partners entering this category.
What’s worth flagging specifically for gynae: because the prescriber base is smaller and more concentrated, the sales ramp-up can initially feel slower than a general medicine franchise with dozens of doctors to approach. Patience through the first two to three months of relationship-building tends to pay off with steadier, more loyal prescribing once gynecologists commit to a brand.
Month one and two are setup — mapping your gynecologist and fertility clinic contacts, placing your first orders, and starting relationship-building visits. Returns are minimal here, which is completely normal across every specialty pharma category, not a sign anything’s wrong.
Months three through six are typically where consistent prescriptions start forming, assuming regular, informed visits to your prescriber list. Partners running a focused gynae range often see monthly turnover cross ₹1-1.5 lakh by month six, particularly once hormone therapy and birth control products build repeat-prescription momentum among regular patients.
Margins in gynae PCD typically run 25-40%, with hormone therapy and infertility-focused products often sitting toward the higher end due to lower competition and stronger prescriber loyalty once trust is established. The consistent pattern among partners who do well here: they don’t spread themselves across too many gynecologists too early. Building deep trust with a focused group of ten to fifteen regular prescribers tends to outperform a scattered approach chasing every clinic in the district at once.
Hormone therapy deserves specific attention within a gynae franchise because of how consistently it drives repeat business. Patients on hormone therapy — whether for menstrual regulation, menopause management, or fertility support — typically stay on treatment for extended periods, which means a single successful prescription relationship can generate months of steady reorders rather than a one-time sale.
This category also tends to reward partners who invest in genuinely understanding the product science, not just the sales pitch. Gynecologists prescribing hormone therapy are making careful, often long-term treatment decisions for their patients, and they notice quickly whether a franchise partner can speak knowledgeably about the formulation or is simply reading off a brochure. Partners who take the time to understand what they’re actually selling tend to build faster, more durable trust in this specific category.
Paperwork gets rushed more than it should, and that’s usually where avoidable delays start. Here’s the real checklist for a gynae PCD franchise.
A valid Drug License — retail and/or wholesale — is required from your state’s Drug Control Department, along with GST registration and a TIN number. Keep your PAN card, address proof, and company profile ready too, since most franchisors, Novalab Gynae Care included, request these at the agreement stage.
Read the franchise agreement carefully before signing. Confirm your territory boundary is named explicitly, check the minimum order requirement expected per month or quarter, and look for a clear exit clause covering notice periods if either side wants to end the partnership. A company confident in its terms won’t hesitate to spell all of this out in writing.
Keep a running file of your license copies, GST certificate, and every invoice from your franchisor. In a specialty category like gynae, gynecologists and fertility specialists occasionally ask for manufacturing documentation before committing to a new brand for their patients, and having it ready builds credibility fast.
A handful of patterns show up repeatedly among partners who struggle in this category, and they’re worth naming directly.
Trying to cover too many gynecologists too early is the most common one. Because the prescriber base is smaller and more specialized than general medicine, spreading thin across every clinic in a district often means shallow, low-trust relationships everywhere instead of strong ones anywhere. Partners who do well tend to focus deeply on ten to fifteen regular prescribers first, then expand once those relationships are solid.
Underestimating the trust-building timeline is second. Hormone therapy and infertility treatment involve sensitive, often long-term patient decisions, and gynecologists take longer to commit to a new brand here than in general prescribing categories. Partners expecting general-medicine-speed results often get discouraged in months two and three, right before relationships typically start solidifying.
Neglecting product knowledge is a mistake specific to this category. Gynecologists prescribing hormone therapy or fertility support notice quickly whether a partner understands the formulation or is simply repeating a brochure. Partners who invest time learning the actual product science build faster, more durable credibility.
And, as with any PCD category, inconsistent reordering erodes trust fast. A gynecologist who recommends a brand and then finds it out of stock at the pharmacy loses confidence quickly, and regaining that trust takes far longer than it took to lose it.
Women’s healthcare in India has shifted meaningfully over the past decade. Fertility treatment has moved from a quiet, stigmatized topic to a mainstream medical path, driven by delayed family planning trends in urban areas and growing awareness that infertility is a treatable medical condition rather than something to hide. Hormone therapy and menstrual health conversations have similarly opened up, supported by better general health literacy and more visible advocacy around women’s health issues.
This shift creates genuine, sustained opportunity for gynae PCD franchise partners. More gynecologists are setting up practice in tier-2 and tier-3 towns, following the same broader trend seen across Indian healthcare, and many of these newer practices are actively looking for reliable pharma partners rather than sticking rigidly to established big-name brands.
Companies that will keep earning long-term partner loyalty in this space are the ones treating the gynae specialty seriously — genuine product depth, responsive support, and consistent supply — rather than treating it as a minor division within a broader, unfocused catalogue.
Case 1 — Hormone therapy and birth control focus, Rajasthan. A partner started with a ₹70,000 initial order concentrated on hormone therapy and birth control products, building relationships with six gynecologists across a single district. Growth was gradual for the first three months, but by month six, monthly turnover crossed ₹1.4 lakh as consistent prescribing patterns formed among established patients on long-term hormone therapy.
Case 2 — Infertility and prenatal range, Madhya Pradesh. Starting investment of around ₹85,000, focused on infertility support medicines and prenatal multivitamins, targeting two fertility clinics and four general gynecologists. The first four months were slow, under ₹40,000 monthly, but consistent, informed visits paid off — turnover reached ₹1.6 lakh by month eight as fertility specialists began prescribing regularly for ongoing patient treatment cycles.
Case 3 — General gynae and gastro combo, Uttar Pradesh. A former medical representative went independent with a ₹60,000 starting order combining general gynae products with gastro medicines aimed at pregnancy-related digestive issues. Leveraging existing doctor relationships from prior MR experience, monthly sales reached ₹1.3 lakh within five months.
These reflect realistic, consistent execution patterns across genuine franchise partners building a gynae-focused business over their first several months.
1. What is a Gynae PCD franchise? A Gynae PCD (Propaganda Cum Distribution) franchise is a business arrangement where a pharma company grants distribution rights for its gynecological and fertility products within a specific territory to an individual or small business.
2. What is the minimum investment to start a gynae PCD franchise with Novalab Gynae Care? Most partners start between ₹50,000 and ₹1.2 lakh, covering initial stock across tablets, syrups, and select injectables along with basic promotional setup.
3. Does Novalab Gynae Care offer monopoly rights? Yes, exclusive distribution rights are offered in dedicated territories to avoid internal competition among the company’s own franchise partners.
4. What product categories does Novalab Gynae Care offer? Hormone therapy medicines, birth control products, multivitamins, gastro medicines, and infertility support formulations across tablets, syrups, injectables, and mix products.
5. What documents are required to start a gynae PCD franchise? A GST number, Drug License, TIN number, and company profile are the core requirements, consistent with standard PCD franchise documentation.
6. Is Novalab Gynae Care ISO and WHO-GMP certified? Yes, the company is ISO-certified and manufactures under WHO-GMP guidelines, with products certified by DCGI.
7. How long does it take to see consistent returns in a gynae PCD franchise? Most partners see steady prescribing patterns forming between month three and six, depending on how consistently they build relationships with gynecologists and fertility specialists.
8. Is a gynae PCD franchise harder to start than a general pharma franchise? The prescriber base is smaller and more specialized, which can mean a slower initial ramp-up, but it typically results in stronger, more loyal prescribing relationships once established.
9. What promotional support does Novalab Gynae Care provide? MR bags, diaries, pen sets, and company literature are provided as standard promotional support for franchise partners.
10. Which gynae product category has the best margins? Hormone therapy and infertility-focused products often carry stronger margins due to lower competition and higher prescriber loyalty once trust is established.
11. Can I add new product categories to my gynae franchise later? Yes, most partners expand into adjacent categories like prenatal supplements or gastro support once their initial range shows steady, consistent movement.
12. Is prior pharma experience necessary to start a gynae PCD franchise? No, though prior experience — particularly as a medical representative — can help compress the initial relationship-building period with gynecologists and fertility specialists.
Starting a gynae PCD franchise comes down to a manageable set of real steps — sort your licensing, map your local gynecologist and fertility clinic base, choose a company genuinely specialized in women’s health, and build trust through consistent, informed visits rather than volume alone.
If you’re ready to explore a gynae PCD franchise with an ISO-certified, WHO-GMP company built specifically around women’s healthcare, get in touch with Novalab Gynae Care today.


Call Us Number +9570599567
Get PCD Pharma Distributorship